Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

In vitro synergy between clofazimine and amikacin in treatment of nontuberculous mycobacterial disease.

van Ingen J, Totten SE, Helstrom NK, Heifets LB, Boeree MJ, Daley CL.

Antimicrob Agents Chemother. 2012 Dec;56(12):6324-7. doi: 10.1128/AAC.01505-12. Epub 2012 Oct 1.

2.

The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatment.

van Ingen J, Egelund EF, Levin A, Totten SE, Boeree MJ, Mouton JW, Aarnoutse RE, Heifets LB, Peloquin CA, Daley CL.

Am J Respir Crit Care Med. 2012 Sep 15;186(6):559-65. doi: 10.1164/rccm.201204-0682OC. Epub 2012 Jun 28.

PMID:
22744719
3.

Drug susceptibility testing and pharmacokinetics question current treatment regimens in Mycobacterium simiae complex disease.

van Ingen J, Totten SE, Heifets LB, Boeree MJ, Daley CL.

Int J Antimicrob Agents. 2012 Feb;39(2):173-6. doi: 10.1016/j.ijantimicag.2011.09.019. Epub 2011 Nov 17.

PMID:
22099521
4.

Are phylogenetic position, virulence, drug susceptibility and in vivo response to treatment in mycobacteria interrelated?

van Ingen J, Boeree MJ, van Soolingen D, Iseman MD, Heifets LB, Daley CL.

Infect Genet Evol. 2012 Jun;12(4):832-7. doi: 10.1016/j.meegid.2011.10.006. Epub 2011 Oct 20. Review.

PMID:
22036704
5.

XDR tuberculosis.

van Ingen J, de Lange WC, Boeree MJ, Iseman MD, Daley CL, Heifets LB, Böttger EC, van Soolingen D.

Lancet Infect Dis. 2011 Aug;11(8):585. doi: 10.1016/S1473-3099(11)70200-6. No abstract available.

PMID:
21798459
6.

Inhibition of M. tuberculosis in vitro in monocytes and in mice by aminomethylene pyrazinamide analogs.

Chung WJ, Kornilov A, Brodsky BH, Higgins M, Sanchez T, Heifets LB, Cynamon MH, Welch J.

Tuberculosis (Edinb). 2008 Sep;88(5):410-9. doi: 10.1016/j.tube.2008.06.001.

PMID:
18674969
7.

Rapid detection of tuberculosis and drug-resistant tuberculosis.

Iseman MD, Heifets LB.

N Engl J Med. 2006 Oct 12;355(15):1606-8. No abstract available.

8.
9.

Cough-generated aerosols of Mycobacterium tuberculosis: a new method to study infectiousness.

Fennelly KP, Martyny JW, Fulton KE, Orme IM, Cave DM, Heifets LB.

Am J Respir Crit Care Med. 2004 Mar 1;169(5):604-9. Epub 2003 Dec 4.

PMID:
14656754
10.

Mycobacterium terrae: case reports, literature review, and in vitro antibiotic susceptibility testing.

Smith DS, Lindholm-Levy P, Huitt GA, Heifets LB, Cook JL.

Clin Infect Dis. 2000 Mar;30(3):444-53. Review.

PMID:
10722426
11.

Drug susceptibility testing of Mycobacterium tuberculosis: a neglected problem at the turn of the century.

Heifets LB, Cangelosi GA.

Int J Tuberc Lung Dis. 1999 Jul;3(7):564-81. Review.

PMID:
10423219
12.
13.

Contribution of rpoB mutations to development of rifamycin cross-resistance in Mycobacterium tuberculosis.

Williams DL, Spring L, Collins L, Miller LP, Heifets LB, Gangadharam PR, Gillis TP.

Antimicrob Agents Chemother. 1998 Jul;42(7):1853-7.

14.

Susceptibilities of Mycobacterium malmoense determined at the growth optimum pH (pH 6.0).

Heginbothom ML, Lindholm-Levy PJ, Heifets LB.

Int J Tuberc Lung Dis. 1998 May;2(5):430-4.

PMID:
9613641
15.

Once weekly azithromycin therapy for prevention of Mycobacterium avium complex infection in patients with AIDS: a randomized, double-blind, placebo-controlled multicenter trial.

Oldfield EC 3rd, Fessel WJ, Dunne MW, Dickinson G, Wallace MR, Byrne W, Chung R, Wagner KF, Paparello SF, Craig DB, Melcher G, Zajdowicz M, Williams RF, Kelly JW, Zelasky M, Heifets LB, Berman JD.

Clin Infect Dis. 1998 Mar;26(3):611-9.

PMID:
9524832
17.

Early bactericidal activity of isoniazid in pulmonary tuberculosis. Optimization of methodology. The DATRI 008 Study Group.

Hafner R, Cohn JA, Wright DJ, Dunlap NE, Egorin MJ, Enama ME, Muth K, Peloquin CA, Mor N, Heifets LB.

Am J Respir Crit Care Med. 1997 Sep;156(3 Pt 1):918-23.

PMID:
9310014
18.

Clinical mycobacteriology. Drug susceptibility testing.

Heifets LB.

Clin Lab Med. 1996 Sep;16(3):641-56. Review.

PMID:
8866184
19.

The mycobacteriology laboratory. Past, present, and future.

Heifets LB.

Clin Lab Med. 1996 Sep;16(3):513-25. Review.

PMID:
8866178
20.

Clarithromycin against Mycobacterium avium complex infections.

Heifets LB.

Tuber Lung Dis. 1996 Feb;77(1):19-26. Review.

PMID:
8733409
21.

Clarithromycin therapy for bacteremic Mycobacterium avium complex disease. A randomized, double-blind, dose-ranging study in patients with AIDS. AIDS Clinical Trials Group Protocol 157 Study Team.

Chaisson RE, Benson CA, Dube MP, Heifets LB, Korvick JA, Elkin S, Smith T, Craft JC, Sattler FR.

Ann Intern Med. 1994 Dec 15;121(12):905-11.

PMID:
7978715
22.

Expedited detection of drug resistance in tuberculosis patients.

Heifets LB.

Ann Emerg Med. 1994 Sep;24(3):457-61. Review.

PMID:
8080143
23.

[Radiometric determination of Mycobacterium avium-intracellulare and Mycobacterium xenopi sensitivity to antitubercular agents].

Kubín M, Lindholm-Levy P, Heifets LB.

Epidemiol Mikrobiol Imunol. 1994 Sep;43(3):104-6. Czech.

PMID:
7953081
24.

Antimycobacterial drugs.

Heifets LB.

Semin Respir Infect. 1994 Jun;9(2):84-103. Review. Erratum in: Semin Respir Infect 1995 Jun;10(2):121.

PMID:
7973175
25.
26.

Rapid broth macrodilution method for determination of MICs for Mycobacterium avium isolates.

Siddiqi SH, Heifets LB, Cynamon MH, Hooper NM, Laszlo A, Libonati JP, Lindholm-Levy PJ, Pearson N.

J Clin Microbiol. 1993 Sep;31(9):2332-8.

27.

Bacteriostatic and bactericidal activities of gentamicin alone and in combination with clarithromycin against Mycobacterium avium.

Heifets LB, Lindholm-Levy PJ, Comstock RD.

Antimicrob Agents Chemother. 1992 Aug;36(8):1695-8.

28.

Clarithromycin minimal inhibitory and bactericidal concentrations against Mycobacterium avium.

Heifets LB, Lindholm-Levy PJ, Comstock RD.

Am Rev Respir Dis. 1992 Apr;145(4 Pt 1):856-8.

PMID:
1532486
29.

Individualized therapy versus standard regimens in the treatment of Mycobacterium avium infections.

Heifets LB, Iseman MD.

Am Rev Respir Dis. 1991 Jul;144(1):1-2. No abstract available.

PMID:
2064112
30.
31.

Thiacetazone: in vitro activity against Mycobacterium avium and M. tuberculosis.

Heifets LB, Lindholm-Levy PJ, Flory M.

Tubercle. 1990 Dec;71(4):287-91.

PMID:
1702564
32.

Choice of antimicrobial agents for M. avium disease based on quantitative tests of drug susceptibility.

Heifets LB, Iseman MD.

N Engl J Med. 1990 Aug 9;323(6):419-20. No abstract available.

PMID:
2370896
33.

MICs and MBCs of Win 57273 against Mycobacterium avium and M. tuberculosis.

Heifets LB, Lindholm-Levy PJ.

Antimicrob Agents Chemother. 1990 May;34(5):770-4.

34.

Bactericidal activity in vitro of various rifamycins against Mycobacterium avium and Mycobacterium tuberculosis.

Heifets LB, Lindholm-Levy PJ, Flory MA.

Am Rev Respir Dis. 1990 Mar;141(3):626-30.

PMID:
2155555
35.

Is pyrazinamide bactericidal against Mycobacterium tuberculosis?

Heifets LB, Lindholm-Levy PJ.

Am Rev Respir Dis. 1990 Jan;141(1):250-2.

PMID:
2105072
36.
37.

Does pyrazinoic acid as an active moiety of pyrazinamide have specific activity against Mycobacterium tuberculosis?

Heifets LB, Flory MA, Lindholm-Levy PJ.

Antimicrob Agents Chemother. 1989 Aug;33(8):1252-4.

40.
41.

Rifabutine: minimal inhibitory and bactericidal concentrations for Mycobacterium tuberculosis.

Heifets LB, Lindholm-Levy PJ, Iseman MD.

Am Rev Respir Dis. 1988 Mar;137(3):719-21.

PMID:
2830815
44.
45.

Response to therapy of pulmonary Mycobacterium avium-intracellulare infection correlates with results of in vitro susceptibility testing.

Horsburgh CR Jr, Mason UG 3rd, Heifets LB, Southwick K, Labrecque J, Iseman MD.

Am Rev Respir Dis. 1987 Feb;135(2):418-21.

PMID:
3813205
46.
47.

Pyrazinamide is not active in vitro against Mycobacterium avium complex.

Heifets LB, Iseman MD, Crowle AJ, Lindholm-Levy PJ.

Am Rev Respir Dis. 1986 Dec;134(6):1287-8.

PMID:
3789528
48.

Rapid automated methods (BACTEC System) in clinical mycobacteriology.

Heifets LB.

Semin Respir Infect. 1986 Dec;1(4):242-9.

PMID:
3120267
49.

Ethambutol MICs and MBCs for Mycobacterium avium complex and Mycobacterium tuberculosis.

Heifets LB, Iseman MD, Lindholm-Levy PJ.

Antimicrob Agents Chemother. 1986 Dec;30(6):927-32.

50.

Dynamic aspects of the in vitro chemotherapeutic activity of ansamycin (rifabutine) on mycobacterium intracellulare.

Perumal VK, Gangadharam PR, Heifets LB, Iseman MD.

Am Rev Respir Dis. 1985 Dec;132(6):1278-80.

PMID:
4073667

Supplemental Content

Loading ...
Support Center